Qiagen NV (N:QGEN)
Business Focus: Biotechnology & Medical Research
May 07, 2024 04:05 pm ET
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for its QIAcuity digital PCR devices that will...
May 02, 2024 04:05 pm ET
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analysis for use with any clinical...
Apr 29, 2024 04:05 pm ET
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the first quarter of 2024. Net sales declined 5% to $459 million, while results at constant exchanges rates (CER) of $462 million were above the outlook for at...
Apr 24, 2024 04:05 pm ET
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world’s leading infectious disease killer....
Apr 09, 2024 09:48 am ET
QIAGEN N.V. to release results for Q1 2024 and hold webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time....
Apr 03, 2024 04:05 pm ET
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy. These three new...
Mar 25, 2024 04:05 pm ET
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade, a significant enhancement to the widely-used QIAstat-Dx Analyzer 1.0 for reliable, fast and...
Mar 18, 2024 04:05 pm ET
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening...
Mar 11, 2024 05:59 am ET
QIAGEN announces Form 20-F annual report filing for 2023 results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and...
Feb 27, 2024 05:44 pm ET
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is...
Feb 27, 2024 04:05 pm ET
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is...
Feb 15, 2024 04:05 pm ET
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced two significant achievements in sustainability through recognitions by My Green Lab, a non-profit organization dedicated to advancing sustainability in scientific research: Two...
Feb 06, 2024 04:05 pm ET
QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2023. Net sales results of $503 million at constant exchange rates (CER) for Q4 2023 achieved the outlook for at least $500 million...
Jan 25, 2024 10:00 am ET
QIAGEN announces partnership with Penn State University to advance microbiome sciences
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. The...
Jan 18, 2024 04:05 pm ET
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a...
Jan 11, 2024 07:53 am ET
QIAGEN N.V. to release results for Q4 2023 and hold webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time /...
Jan 08, 2024 02:00 am ET
QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx...
Jan 07, 2024 01:07 pm ET
QIAGEN announces plans to return approximately $300 million to shareholders
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a...
Jan 04, 2024 04:05 pm ET
QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These investments will support QDI, the...
Jan 03, 2024 02:00 am ET
QIAGEN expands business in Middle East with new regional headquarters and major projects
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant expansion of its business in the Middle East region, which includes three major developments: In early 2024, QIAGEN will open its regional headquarters in Riyadh,...
Nov 30, 2023 04:05 pm ET
DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DNA Labs International announced today that DLI has recently solved two decades-old “cold cases” using QIAGEN solutions. The products involved are ForenSeq Kintelligence System for forensic...
Nov 15, 2023 04:05 pm ET
QIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing diverse materials such as bone, tissue and...
Nov 09, 2023 04:05 pm ET
QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three new kits for use on its QIAcuity systems and a major new software update designed to expand the portfolio of applications for use of digital PCR technology in...
Nov 06, 2023 04:05 pm ET
QIAGEN launches complete Sample to Insight workflow for microbiome research
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in...
Nov 02, 2023 08:00 am ET
QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today announced a strategic partnership to offer comprehensive next-generation sequencing (NGS) workflows for the Element AVITI™ System, an innovative sequencing...
Nov 02, 2023 08:00 am ET
QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System
Partnership combines QIAGEN's QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element's AVITI System users in genomic analysisElement and QIAGEN are advancing genomic applications with innovative technology and complete next-generation sequencing (NGS) workflows for researchersPartnership to accelerate discovery, enhance cost efficiencies, and improve turnaround times for genomic applications in the scientific communityVENLO, Netherlands, and SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today ann
Oct 30, 2023 04:05 pm ET
QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter and first nine months of 2023. Net sales results of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465...
Oct 26, 2023 08:00 am ET
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative...
Oct 26, 2023 08:00 am ET
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative...
Oct 09, 2023 11:14 am ET
QIAGEN N.V. to release results for Q3 2023 and hold webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York...
Oct 04, 2023 04:05 pm ET
QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay. Epstein-Barr virus (EBV), or human herpes virus 4, is estimated in various epidemiological studies to be positive in...
Sep 28, 2023 04:05 pm ET
QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), to include artificial intelligence (AI)-enhanced coverage of thousands of...
Sep 27, 2023 04:05 pm ET
QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of its Sustainability Report 2022, emphasizing its unwavering focus on driving positive change for society through its goals for Environment, Social and Governance (ESG)...
Sep 25, 2023 04:05 pm ET
QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of its eco-friendlier QIAwave product line with the addition of two new nucleic acid extraction kits: the QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit,...
Aug 08, 2023 04:05 pm ET
QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter and first half of 2023. Net sales results of $497 million at constant exchange rates (CER) for Q2 2023 were above the outlook for at least $490 million...
Aug 07, 2023 04:05 pm ET
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit). This companion diagnostic is intended for use to aid...
Jul 26, 2023 04:15 pm ET
Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a...
Jul 26, 2023 04:15 pm ET
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
Jul 24, 2023 07:41 am ET
QIAGEN N.V. to release results for Q2 2023 and hold webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023. Press release date / time: Tuesday, August 8, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York...
Jul 18, 2023 04:05 pm ET
QIAGEN expands range of digital PCR kits and services for the biopharma industry
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its digital PCR (dPCR) offering for the development of cell and gene therapies in the biopharma industry. The company has partnered with Niba Labs to offer...
Jun 20, 2023 04:05 pm ET
FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that the U.S. Federal Bureau of Investigation (FBI) has approved its ForenSeq® MainstAY workflow. This allows accredited forensic DNA laboratories to process DNA casework samples...
Jun 16, 2023 07:36 am ET
QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notes
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecured Convertible Notes due 2023 (the "2023 Notes") –...
Jun 15, 2023 04:05 pm ET
QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new, systematic review highlighting the unique value of its proprietary tuberculosis (TB) testing technology. The study highlights QIAGEN’s continued leadership in TB...
Jun 13, 2023 04:05 pm ET
Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) Interpret, is being deployed as a part of a national initiative in Denmark to offer...
May 03, 2023 04:05 pm ET
QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the first quarter of 2023. Net sales for Q1 2023 declined 23% (-20% at constant exchange rates, CER) to $485 million from Q1 2022, which was marked by very strong COVID-19...
May 03, 2023 05:30 am ET
QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care...
Apr 24, 2023 04:05 pm ET
QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QIAstat-Dx syndromic testing solution is expected to be available soon for use in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a...
Apr 20, 2023 04:05 pm ET
QIAGEN announces expansion of Supervisory Board
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a...
Apr 14, 2023 06:00 am ET
QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries...
Mar 29, 2023 08:00 am ET
QIAGEN’s QIAxcel Connect wins Red Dot design award
QIAGEN today announced that QIAxcel Connect, its high-resolution gel electrophoresis instrument for use with DNA or RNA samples, has won the prestigious Red Dot award. This marks the fourth instrument from QIAGEN to receive this award from one of...
Mar 27, 2023 08:00 am ET
QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s...
Mar 13, 2023 08:01 am ET
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website
Mar 09, 2023 01:30 am ET
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
Mar 01, 2023 09:00 am ET
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.
Feb 14, 2023 04:05 pm ET
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the certification of QuantiFERON-TB Gold Plus (QFT-Plus) – the world’s leading tuberculosis (TB) blood test – under the European Union’s 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR) which is replacing the 98/79/EC In Vitro Diagnostic Directive (IVDD). QFT-Plus is QIAGEN’s trusted test, endorsed by the WHO, that aids in indirect detection of the bacteria that causes tuberculosis (TB). The IVDR certification of QFT-Plus follows the QIAGEN ipsogen JAK2 RGQ PCR Kit as well as the NeuMoDx Systems and re
Feb 07, 2023 04:05 pm ET
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2022.
Jan 17, 2023 04:05 pm ET
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after being made available for research.
Jan 17, 2023 06:38 am ET
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.
Jan 09, 2023 02:00 am ET
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation.
Jan 05, 2023 04:05 pm ET
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.
Jan 05, 2023 03:05 pm ET
Helix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary Diseases
Partnership to leverage the Helix® Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Addressing health burden in neuro-degenerative diseases, cardiovascular diseases, and auto-immune and inflammatory diseases that affect hundreds of millions globallyComplementary to the products and services both companies offer including accelerated patient recruitment, real world evidence, research services leveraging clinico-genomic datasets and diagnostic solutions using NGS and PCR technologiesSAN MATEO, Calif. And VENLO, The Netherlands, Jan. 5,
Dec 13, 2022 05:00 am ET
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen® KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic’s drug KRAZATI® (adagrasib) for non-small cell lung cancer (NSCLC).
Nov 21, 2022 04:05 pm ET
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the monkeypox (MPXV) test for its NeuMoDx automated PCR platform to strengthen surveillance and research into the current outbreak in non-endemic regions that has infected tens of thousands of people all over the world since first being identified in May 2022.
Nov 07, 2022 04:05 pm ET
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter of 2022 and first nine months of 2022, and increased the outlook for full-year 2022.
Oct 21, 2022 06:54 am ET
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter of 2022.
Sep 16, 2022 04:20 am ET
IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners
IGI Inex will obtain a relevant share position based on quantumrock's valuation of €30 million with the right to extend its share position over time
Sep 15, 2022 04:05 pm ET
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses. The new assays for the identification and quantification of the Epstein-Barr virus (EBV) and the human herpesvirus 6 (HHV-6) have received CE-IVD certification for the European Union and other countries that accept this marking.
Sep 14, 2022 04:05 pm ET
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.
Sep 14, 2022 04:01 pm ET
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug
Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN's long-standing experience in companion diagnostic development
Aug 18, 2022 04:05 pm ET
QIAGEN Issues 2021 Sustainability Report
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2021 Sustainability Report, outlining significant achievements in the areas of Environment, Social and Governance (ESG) as part of its strategy to become a stronger and more sustainable leader in providing Sample to Insight solutions that unlock valuable molecular insights for customers in the Life Science and Molecular Diagnostics industries.
Aug 15, 2022 04:05 pm ET
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms.
Jul 27, 2022 01:40 am ET
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers, particularly those involved in the biopharma industry:
Jul 26, 2022 01:49 pm ET
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022.
Jul 19, 2022 04:05 pm ET
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its decision-support software platform QIAGEN Clinical Insights (QCI) has been used to interpret more than three million patient molecular profiles for hereditary and oncological diseases to date. This milestone for the QCI portfolio of clinical software and professional services for the interpretation and reporting of variants from next-generation sequencing (NGS) testing underscores QIAGEN’s leadership position in precision medicine. The platform, incepted only seven years ago, is currently growing at 35% or 700,000 addi
Jul 07, 2022 06:00 am ET
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter of 2022.
Jun 01, 2022 04:05 pm ET
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomed an endorsement from the National Wastewater Surveillance System (NWSS) of the U.S. Centers for Disease Control and Prevention (CDC) and their validation and approval for the use of two digital PCR systems – including the QIAcuity digital PCR system – for wastewater surveillance of 30 pathogens, including the SARS-CoV-2 virus.
May 19, 2022 04:05 pm ET
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its recently launched, environmentally friendlier QIAwave nucleic-acid extraction kits have received the prestigious ACT Environmental Impact Factor Label from My Green Lab, a non-profit organization dedicated to advancing sustainability in scientific research.
May 16, 2022 01:30 am ET
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.
May 11, 2022 10:24 am ET
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has signed agreements to acquire a 96% majority ownership stake in BLIRT SA (Polish Stock Exchange: BLR), a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland.
May 11, 2022 02:00 am ET
QIAGEN Proposes Expansion of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the proposal of Dr. Eva Pisa, a leader in health diagnostics and biotechnology who has extensive experience from start-ups to corporate companies, as a new member of the Supervisory Board.
May 05, 2022 01:30 am ET
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) has received CE-IVD certification for the European Union and other countries that accept this marking.
Apr 26, 2022 02:00 pm ET
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the first quarter of 2022 and increased the outlook for full-year 2022.
Apr 20, 2022 12:45 pm ET
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release results for the first quarter of 2022 on Wednesday, April 27, at approximately 22:05 Frankfurt time / 21:05 London time / 16:05 New York time
Mar 24, 2022 02:30 am ET
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis (TB) infection more than 100 million times since its launch – an achievement that cements its status as the gold standard in the fight against this contagious and often deadly disease.
Mar 14, 2022 09:02 am ET
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website
Feb 08, 2022 04:05 pm ET
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021.
Feb 07, 2022 01:30 am ET
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has gained additional momentum with the approval of the fourth generation of this modern gold standard test in China and a new endorsement from the World Health Organization (WHO).
Jan 27, 2022 12:29 pm ET
QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its commitment to workplace diversity and gender equality has been recognized by inclusion in the U.S. LGBTQ+ Corporate Equality Index (CEI) of the Human Rights Campaign Foundation and the global Bloomberg Gender-Equality Index (GEI).
Jan 25, 2022 01:30 am ET
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has completed a U.S. government contract to equip public health laboratories across the country with the QIAcuity digital PCR system to monitor the spread of the COVID-19 pandemic by testing wastewater for the presence of SARS-CoV-2 pathogens.
Jan 19, 2022 08:20 am ET
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8, at approximately 16:05 Eastern Standard Time (EST) / 22:05 Central European Time (CET).
Jan 18, 2022 04:05 pm ET
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste than existing ones. They are the first of their type to use both recycled plastics and space-saving chemical concentrates.
Jan 10, 2022 10:12 am ET
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample – with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer.
Jan 07, 2022 01:30 am ET
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems.
Jan 06, 2022 04:05 pm ET
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases.
Dec 09, 2021 08:30 am ET
Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
SAN DIEGO and GERMANTOWN, Md. and HILDEN, Germany, Dec. 9, 2021 /PRNewswire/ -- Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1™) who are likely to respond to Denovo's investigational cancer drug DB102™ for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.
Dec 09, 2021 01:30 am ET
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who are likely to respond to Denovo’s investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.
Dec 02, 2021 01:10 am ET
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.
Nov 29, 2021 01:10 am ET
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.
Nov 26, 2021 09:18 am ET
QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa.
Nov 16, 2021 10:00 am ET
Thinking about trading options or stock in Qiagen NV, NetEase, Boeing, Hollysys Automation Technologies, or Walmart?
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QGEN, NTES, BA, HOLI, and WMT.
Nov 08, 2021 04:05 pm ET
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its commitment to a science-based target of net-zero carbon emissions by 2050 in order to help limit global warming to 1.5˚C. This move supports the goals set out by the Paris Climate Agreement and marks an important milestone in QIAGEN’s sustainability efforts.
Nov 05, 2021 04:05 pm ET
QIAGEN and BD Settle Patent Infringement Lawsuit
QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that they have reached a settlement in the patent infringement lawsuit related to QIAGEN’s NeuMoDx™ 96 and NeuMoDx™ 288 clinical PCR systems that QIAGEN acquired from NeuMoDx Inc. in 2020.
Nov 03, 2021 04:08 pm ET
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter and first nine months of 2021.
Nov 02, 2021 04:05 pm ET
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE-marking of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2.
Oct 22, 2021 06:00 am ET
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchester’s CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.
Oct 20, 2021 09:20 am ET
QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the third quarter and first nine months of 2021 on Wednesday, November 3, at approximately 21:05 Central European Time (CET) / 16:05 Eastern Daylight Time (EDT).
Oct 19, 2021 04:05 pm ET
QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE marking of QIAreach® QuantiFERON®-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing access to easy and reliable TB testing, especially in high burden countries, low-resource regions.
Oct 05, 2021 07:45 am ET
Quotient Limited Announces Appointment of Chief Commercial Officer
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company’s Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it...
Sep 30, 2021 04:48 pm ET
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it had won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems, an important step to support laboratory testing as the COVID-19 pandemic continues.
Sep 03, 2021 04:10 pm ET
QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has been chosen to be included in the DAX (Deutscher Aktienindex), the leading German stock market index in Germany.
Aug 23, 2021 04:05 pm ET
QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the number of biological samples processed with consumables kits has passed the three billion mark – a record that underlines its leadership in enabling molecular laboratories to gain valuable insights in research, combatting diseases and forensics.
Aug 10, 2021 04:05 pm ET
QIAGEN and GT Molecular Collaborate to Offer a Complete SARS-CoV-2 Wastewater Detection Solution Based on QIAcuity Digital PCR Technology
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and GT Molecular, a leader in providing customizable, highly sensitive digital PCR and qPCR tests based in the U.S., have started to offer a complete wastewater workflow solution designed to enable surveillance of COVID-19 outbreaks by U.S. and Canadian laboratories, with future options to offer the solution in other countries.
Aug 09, 2021 04:05 pm ET
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced signing a master companion diagnostics (CDx) agreement to develop a NGS CDx for OncXerna’s product candidate, Navicixizumab, and a non-exclusive license to the Xerna™ TME panel.
Aug 06, 2021 01:15 pm ET
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its QIAreach® SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results.
Jul 30, 2021 09:31 am ET
Thinking about trading options or stock in Atlassian, Crispr Therapeutics, Qiagen, Apple, or Pfizer?
NEW YORK, July 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TEAM, CRSP, QGEN, AAPL, and PFE.
Jul 29, 2021 04:14 pm ET
QIAGEN Reports Full Results for Q2 and H1 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced full results for the second quarter and first half of 2021 that were in line with the preliminary announcement on July 12.
Jul 12, 2021 11:55 am ET
QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today has released preliminary Q2 2021 results and an updated outlook for full-year 2021.
Jul 12, 2021 11:15 am ET
QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced preliminary results for the second quarter of 2021 that exceeded the outlook for net sales and adjusted earnings per share.
Jul 08, 2021 04:22 pm ET
QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx™ HAdV Quant Assay for the identification and quantification of human adenovirus (HAdV) DNA has received CE-IVD certification for the European Union and other countries that accept this marking.
Jul 07, 2021 04:05 pm ET
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the Workflow Configurator, enabling researchers in the life sciences to easily and quickly find the best solutions to optimize their experiments.
Jul 01, 2021 01:59 am ET
QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global strategic alliance with Japan’s Sysmex Corporation (Tokyo Stock Exchange, First Section [Ticker Code: 6869]) for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).
Jun 29, 2021 04:07 pm ET
Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and Verogen Inc. today announced a partnership to provide laboratories with superior tools and comprehensive support for implementing next-generation sequencing (NGS) human identification workflows.
Jun 29, 2021 04:05 pm ET
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a commercialization partnership with San Diego-based human identification specialist Verogen that will provide customers of both companies with superior tools and comprehensive support for human identification (HID) workflows in their laboratories.
Jun 21, 2021 04:05 pm ET
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.
May 28, 2021 01:45 pm ET
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen® KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN).
May 25, 2021 04:05 pm ET
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s invest
May 17, 2021 06:15 am ET
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the creation of a Scientific Advisory Board as well as updates on the Supervisory Board ahead of the Annual General Meeting in June 2021.
May 12, 2021 04:05 pm ET
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach® Anti-SARS-CoV-2 Total Test.
May 03, 2021 04:05 pm ET
QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the first quarter of 2021, exceeding the goals for net sales and adjusted earnings per share.
Apr 29, 2021 04:05 pm ET
QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the upcoming launch of the EZ2 Connect product line, a next-level automated sample-processing platform whose simplicity, flexibility and speed will benefit biomedical research, forensics and clinical diagnostics.
Apr 21, 2021 01:00 am ET
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the launch of the LIAISON® LymeDetect® Assay for markets accepting the CE Mark, as an aid to detect early Lyme Borreliosis infection (Lyme) on LIAISON® analyzer systems.
Apr 20, 2021 04:05 pm ET
QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the artus® SARS-CoV-2 Prep&Amp UM Kit which uses a liquid based sample preparation technology to simplify and increase COVID-19 testing throughput. The artus® SARS-CoV-2 Prep&Amp UM Kit has been CE-IVD registered for use in the European Union and other markets and an application for Emergency Use Authorization (EUA) has been submitted to the FDA, allowing commercialization via notification in the US.
Apr 20, 2021 05:55 am ET
QIAGEN N.V. to Report First Quarter 2021 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2021 on Monday, May 3, at approximately 22:05 Central European Time (CET) / 16:05 Eastern Daylight Time (EDT).
Apr 06, 2021 04:05 pm ET
QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the launch of QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly reduces library turnaround times and plastics use compared with ARTIC project protocols (primer-based approaches for next-generation sequencing (NGS)). The lab and bioinformatic protocols of the ARTIC network, an initiative funded by the Wellcome Trust, are considered the gold standard in NGS-based characterization of SARS-CoV-2 genomes.
Mar 29, 2021 02:00 am ET
QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Emergency Use Authorization by the U.S. FDA for the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help healthcare professionals quickly identify and differentiate individuals suspected by a healthcare provider of respiratory viral infection consistent with COVID-19.
Mar 05, 2021 06:05 am ET
QIAGEN Announces 20-F Annual Report Filing for 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2020, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website at
Mar 03, 2021 04:10 pm ET
QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.
Mar 02, 2021 04:11 pm ET
QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of the QIAcube Connect MDx, a flexible platform for automated sample processing that will now be available to molecular diagnostic laboratories in the U.S. and Canada, the European Union and other markets worldwide.
Feb 24, 2021 01:45 am ET
QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies.
(*Complementary when referring to the US regulatory pathway.)
Feb 24, 2021 12:45 am ET
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.)
Feb 22, 2021 04:08 pm ET
QIAGEN Expands Supervisory Board With Appointment of a New Member
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect.
Feb 09, 2021 04:05 pm ET
QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the fourth quarter and full-year 2020, exceeding the goals for net sales and adjusted earnings per share.
Jan 28, 2021 04:05 pm ET
QIAGEN Adds dPCR Platform QIAcuity to Growing Portfolio of COVID-19 Testing Solutions for Wastewater and Mutation Testing
QIAGEN today announced the addition of kits for wastewater testing to its growing portfolio of COVID-19 products. The use of dPCR in the worldwide surveillance of COVID-19 is an additional step towards making digital PCR (dPCR) an affordable and standard instrument for a host of applications in molecular-testing laboratories worldwide.
Jan 26, 2021 07:10 am ET
QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year 2020 on Tuesday, February 9,at approximately 22:05 Central European Time (CET) / 16:05 Eastern Standard Time (EST).
Jan 20, 2021 04:08 pm ET
QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 minutes.
Jan 20, 2021 04:05 pm ET
QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections – and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral variants by established testing methods.
Jan 08, 2021 07:00 am ET
QIAGEN Announces Appointment of New Supervisory Board Member
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. He will also become a member of the Audit Committee.
Dec 17, 2020 04:05 pm ET
QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard QIA) announced today that it has successfully concluded a syndicated revolving credit facility for EUR 400mn with an interest rate linked to the company’s environmental, social and governance (ESG) performance.
Dec 08, 2020 01:45 am ET
QIAGEN Increases Outlook for 2020 and 2021
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has raised its full-year 2020 outlook for growth of net sales and adjusted earnings per share (EPS) and is looking forward to another strong performance in 2021.
Dec 07, 2020 02:00 am ET
QIAGEN to Launch QuantiFERON SARS-CoV-2 For Research Into Causes, Spread and Control of COVID-19 Through T-cell Response
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect T-cell responses of the human immune system to the pathogen that causes COVID-19, which could help researchers find out more about immunity levels and disease progression.
Nov 18, 2020 04:05 pm ET
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration with BioNTech SE (Nasdaq: BNTX) to develop and commercialize a tissue-based companion diagnostic – to be used with investigational cancer treatment BNT113 – which identifies patients with squamous cell carcinoma of the head and neck (SCCHN) that are caused by specific infections by human papilloma virus (HPV).
Nov 17, 2020 07:00 am ET
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
WASHINGTON, Nov. 17, 2020 /PRNewswire/ -- Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences (NASDAQ: EXAS), Foundation Medicine, Illumina (NASDAQ: ILMN), LabCorp (NYSE: LH), QIAGEN (NYSE: QGEN), Roche Diagnostics (SIX: RO, ROG: OTCQX: RHHBY), and Thermo Fisher Sc
Nov 16, 2020 04:05 pm ET
QIAGEN Launches NeuMoDx Multiplex Test to Complete Range of SARS-CoV-2 Testing Solutions in Europe and Other Markets
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the European launch of the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test that will help healthcare professionals quickly identify and differentiate between patients with common seasonal respiratory infections and COVID-19.
Nov 11, 2020 04:05 pm ET
QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has started commercialization of a portable digital test in the United States that can be used by laboratories to detect SARS-CoV-2 antigens in people with active infections in 2-15 minutes. A point of care (POC) claim will be added and EUA amended later this year.
Oct 27, 2020 01:04 pm ET
QIAGEN N.V. to hold investor call on Wednesday, October 28, after releasing results for Q3 2020 and first nine months of 2020
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced it would hold a conference call on Wednesday, October 28, after releasing full results for the third quarter and first nine months of 2020 on Tuesday, October 27.
Oct 27, 2020 12:59 pm ET
QIAGEN Reports Strong Results for Third Quarter and First Nine Months of 2020 and Increases Outlook for Full-Year 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong full results of operations for the third quarter and first nine months of 2020 and also increased its outlook for net sales and adjusted earnings per share (EPS) for full-year 2020.
Oct 13, 2020 08:45 am ET
QIAGEN reports strong preliminary results for third quarter of 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020.
Oct 05, 2020 04:03 pm ET
QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a novel straightforward approach to viral RNA epidemiology that will significantly simplify and accelerate PCR analysis and remove key testing bottlenecks for SARS-CoV-2 and other RNA viruses.
Sep 17, 2020 04:05 pm ET
QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.
Sep 08, 2020 04:02 pm ET
QIAGEN to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour for SARS-CoV-2 Antigen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a rapid portable test that can detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes and process on average around 30 swab samples per hour using a small digital detection system.
Aug 24, 2020 04:02 pm ET
QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that provides results in about 10 minutes to detect antibodies in people exposed to the SARS-CoV-2 virus, which is the case of COVID-19.
Aug 21, 2020 11:52 am ET
QIAGEN announces new Chairman of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced today a transition in the leadership of its Supervisory Board after an extraordinary meeting of the Supervisory Board and Managing Board.
Aug 18, 2020 04:05 pm ET
QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated analysis and interpretation workflows for insights into the evolution and spread of the virus that causes COVID-19 disease. The new products are an expansion of QIAGEN’s broad offering of sample technologies, diagnostic tests and instruments, and research tools for use in the global effort to combat the COVID-19 pandemic.
Aug 13, 2020 08:30 am ET
QIAGEN to Continue Successful Growth Strategy Focused on Execution and Greater Value Creation After Voluntary Public Takeover Offer Falls Short
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.
Aug 10, 2020 04:01 pm ET
HTG Molecular Diagnostics Announces New Commercialization and Distribution Agreement for Companion Diagnostics with QIAGEN
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signing of a Commercialization and Distribution Agreement (Master Agreement) with QIAGEN Manchester...
Aug 04, 2020 04:06 pm ET
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced full results of operations for the second quarter and first half of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on July 9, 2020, and July 13, 2020. Net sales for the second quarter of 2020 grew 16% over the second quarter of 2019 (+19% at constant exchange rates, or CER), and adjusted earnings per share were $0.56 CER (+70% CER) for the quarter.
Jul 22, 2020 06:00 am ET
QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Supplemental Reasoned Position Statement in response to the amended Offer Document published by Thermo Fisher Scientific Inc (NYSE: TMO) on July 17, 2020. The Offer Document relates to the recommended offer by Thermo Fisher to fully acquire all issued ordinary shares in QIAGEN for an increased offer price of €43.00 per QIAGEN share in cash, as announced on July 16, 2020.
Jul 16, 2020 08:45 am ET
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement
WALTHAM, Mass. and VENLO, The Netherlands, July 16, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of Sample to Insight molecular diagnostics and sample preparation technologies, today announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.
Jun 30, 2020 01:55 pm ET
QIAGEN Shareholders Approve All Agenda Items Related to Acquisition by Thermo Fisher Scientific at Annual General Meeting
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that its shareholders today approved all agenda items at the Company’s Annual General Meeting related to the proposed voluntary public takeover offer for the acquisition of all ordinary shares in QIAGEN by Quebec B.V., a wholly-owned subsidiary of Thermo Fisher Scientific Inc. (NYSE: TMO) for EUR 39 per share in cash (the “Offer”).
Jun 22, 2020 04:05 pm ET
QIAGEN Announces Plans to Release Preliminary Q2 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it plans to provide in the first half of July 2020 an overview of preliminary results for the second quarter and first half of 2020, along with perspectives on anticipated business trends for the third quarter of 2020. The release of full second quarter 2020 results remains planned for August 4, 2020.
Jun 18, 2020 11:30 pm ET
Rigrodsky & Long, P.A. Files Class Action Suit Against QIAGEN N.V.
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of QIAGEN N.V. (“QIAGEN” or the “Company”) (NYSE: QGEN) common stock in connection...
May 28, 2020 04:05 pm ET
QIAGEN Builds on Leading Position in Precision Medicine With Novel Solutions in Oncology
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer – accelerating multiple applications of Precision Medicine. QIAGEN is showcasing its broad portfolio of Sample to Insight solutions for cancer in connection with the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from May 29-31.
May 18, 2020 07:00 am ET
Thermo Fisher Scientific Publishes Offer Document for Voluntary Tender Offer for All Ordinary Shares of QIAGEN N.V.
WALTHAM, Mass., May 18, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published the offer document (the "Offer Document") for its voluntary tender offer (the "Tender Offer") for all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) at an offer price of €39 per share in cash, following approval of the publication by the German Federal Financial Supervisory Authority.
May 18, 2020 03:18 am ET
QIAGEN Announces Publication of Reasoned Position Statement for Proposed Acquisition by Thermo Fisher and Date for Annual General Meeting
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Reasoned Position Statement in response to the Offer Document published by Thermo Fisher Scientific Inc (NYSE: TMO) earlier today. The Offer Document relates to the recommended offer by Thermo Fisher to fully acquire all issued shares in QIAGEN as announced on March 3, 2020.
May 18, 2020 03:15 am ET
Thermo Fisher Scientific Publishes Offer Document for Voluntary Tender Offer for All Ordinary Shares of QIAGEN N.V.
WALTHAM, Mass., May 18, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published the offer document (the "Offer Document") for its voluntary tender offer (the "Tender Offer") for all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) at an offer price of €39 per share in cash, following approval of the publication by the German Federal Financial Supervisory Authority.
May 06, 2020 04:05 pm ET
QIAGEN Reports Full Results for First Quarter of 2020
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announced full results of operations for the first quarter of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on April 9, 2020. Net sales grew 7% (+9% at constant exchange rates, or CER) and adjusted earnings per share were $0.34 CER.
May 05, 2020 04:55 pm ET
QIAGEN Expects Higher Results for Q2 2020 Based on Trends to Date and Suspends Outlook for Full-Year 2020
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announces that, based on trends to date, it currently expects net sales growth of at least 12% at constant exchange rates (CER) and adjusted earnings per share (EPS) of at least $0.40 CER for the second quarter of 2020 compared to the same period in 2019.
Apr 30, 2020 09:00 am ET
QIAGEN posts IFRS Annual Report for 2019 results and 2019 Annual Report on its website
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at:
Apr 23, 2020 07:52 am ET
QIAGEN N.V. to Report First Quarter 2020 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2020 results on Wednesday, May 6, at approximately 22:05 Central European Time (CET) / 16:05 Eastern Day Time (EDT).
Apr 20, 2020 10:57 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal?
NEW YORK, April 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:
Apr 15, 2020 04:05 pm ET
QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer
Colorectal cancer is the third most common type of cancer, and approximately 150,000 patients a year in the United States are diagnosed with CRC. In primary and metastatic CRC, BRAF mutations (nearly always V600E) are present in up to 15% of patients and are thought to be key drivers of tumor growth. Detection of the V600E mutation utilizing the therascreen BRAF V600E assays will help identify patients eligible for treatment with the newly approved combination of BRAFTOVI and cetuximab. The therascreen BRAF V600E kit runs on QIAGEN’s Rotor-Gene Q MDx, a member of the modular QIAs
Apr 09, 2020 12:30 pm ET
QIAGEN Announces Preliminary Q1 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020.
Apr 02, 2020 02:55 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Mobile Mini, Inc. (MINI), Qiagen N.V., (QGEN), Taubman Centers, Inc. (TCO) and Wright Medical Group N.V. (WMGI)
Mobile Mini, Inc. (MINI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MINI to Willscott Corporation ("WSC") for approximately $40.42 per share. If you are a MINI...
Mar 31, 2020 04:05 am ET
QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.
Mar 26, 2020 03:30 pm ET
ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V.
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V. (NYSE: QGEN) resulting from allegations that Qiagen may have issued materially misleading business information to the investing public.
Mar 24, 2020 02:11 pm ET
SHAREHOLDER INVESTIGATION: Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – NTGN, FSB, FSCT, QGEN
Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the...
Mar 24, 2020 01:00 pm ET
QIAGEN Names Thierry Bernard as Chief Executive Officer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Thierry Bernard has been named Chief Executive Officer.
Mar 24, 2020 05:30 am ET
QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has begun shipments to the United States of its new QIAstat-Dx Respiratory SARS-CoV-2 Panel test to aid in diagnosing patients infected with the novel COVID-19 coronavirus under a new Policy of the U.S. Food and Drug Administration (FDA) announced on March 16. QIAGEN will submit this week the related Emergency Use Authorization (EUA) to the FDA.
Mar 23, 2020 04:21 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Neon Therapeutics, Inc., Qiagen N.V., Stein Mart, Inc., and Taubman Centers, Inc.
Neon Therapeutics, Inc. (NTGN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of NTGN to BioNTech SE. If you are a NTGN investor, and would like additional information about our...
Mar 18, 2020 07:00 pm ET
QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has obtained CE marking for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2.
Mar 17, 2020 04:09 pm ET
QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19.
Mar 17, 2020 03:39 pm ET
CENTOGENE Announces Changes in Supervisory Board
CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced changes to...
Mar 16, 2020 12:19 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Qiagen N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or “the Company”) (NYSE:
Mar 13, 2020 09:01 am ET
QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will develop a new QIAstat-Dx test kit to differentiate the novel SARS-CoV-2 coronavirus from 21 other serious respiratory infections and will receive advanced development support from the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). Accelerated development of the QIAstat-Dx test kit further expands QIAGEN’s global mobilization for the emergency, which already includes a dramatic increase in production of components for a full range of U.S. and internat
Mar 11, 2020 03:39 pm ET
Lifshitz & Miller LLP Announces Investigation of Forty Seven, Inc., Mobile Mini, Inc., Qiagen N.V. and The Meet Group, Inc.
Forty Seven, Inc. (NASDAQ:FTSV) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of FTSV to Gilead Sciences, Inc. for $95.50 per share. If you are a FTSV investor, and would like...
Mar 10, 2020 05:18 pm ET
Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of the Following Companies – WLTW, LM, QGEN, WMGI
Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the...
Mar 10, 2020 01:52 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Qiagen N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or “the Company”) (NYSE:
Mar 09, 2020 08:09 pm ET
Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of QIAGEN, The Meet Group, and Willis Tower Watson on behalf of Stockholders and Encourages Investors to Contact
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of QIAGEN N.V. (NYSE: QGEN), The Meet Group, Inc. (NASDAQ: MEET), and Willis Towers Watson Public Limited Company (NASDAQ:...
Mar 09, 2020 01:30 pm ET
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V. – QGEN
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V. (NYSE: QGEN) resulting from allegations that Qiagen may have issued materially misleading business...
Mar 03, 2020 12:27 pm ET
QIAGEN MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Qiagen N.V. is Fair to Shareholders; Investors are Encouraged to Contact the Firm – QGEN
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of QIAGEN N.V. (NYSE: QGEN) to Thermo Fisher Scientific Inc. is fair to QIAGEN shareholders. On behalf of QIAGEN shareholders, Halper Sadeh LLP may seek...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.